12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday’s after-market session. The company’s market cap…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday’s after-market session. The market value of their…
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday’s after-market session. The market value of their…
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday’s after-market session. The company’s market cap stands…
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today’s pre-market trading after the company reported…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday’s pre-market session. The market value of…
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday’s after-market session. The company’s market cap stands…
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday.
The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.